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with arrhythmias not responding to the conventional treatment.
Since catheter ablation became a standard procedure in the treatment of arrhythmia, the guidelines were revised in 2006 2 to expand the indications for catheter ablation for supraventricular tachycardia as well as complex arrhythmias including AF. After the revision in 2006, catheter ablation became more common especially in the treatment of paroxysmal AF in which pulmonary vein isolation became the standard catheter ablation procedure. In the "Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008) 3 " and the "Guidelines for Drug Treatment of Arrhythmias (JCS 2009) 4 ", catheter ablation is recommended as second-line therapy for drug-resistant AF. In these guidelines, catheter ablation is also recommended as second-line therapy for other types of arrhythmias not respond to pharmacotherapy and even as first-line therapy for selected patients. The performance of 3D mapping systems was improved as the CARTO XP and CARTO 3, the second and third generations of the CARTO system were approved in 2008 and 2011, respectively, and EnSite NavX, a new feature of EnSite, was approved in 2009. Irrigation tip catheters, that had been unavailable in Japan despite the availability in other countries, were introduced in Japan in 2009. With the advancement of these techniques to support catheter ablation, there is the need for wider and clearer indications of catheter ablation in the treatment of complex arrhythmias especially refractory ones such as AF and ventricular tachycardia.
When the first edition of the guidelines was prepared in 1999 to 2000, the use of implantable cardioverter-defibrillator (ICD) was quite limited in Japan, and almost no evidence was available. In the guidelines, ICD therapy was thus indicated mainly for secondary prevention of sudden cardiac death (SCD) according to the findings of large-scale clinical studies in Europe and the United States and consensus of specialists in Japan, as well as for primary prevention of SCD in patients with a high risk of fatal arrhythmias who have either nonsustained ventricular tachycardia or syncope of unknown etiology, show ventricular dysfunction, and have inducible ventricular tachycardia/fibrillation in electrophysiological studies (EPS) according to the results of the MADIT (Multicenter Automatic Defibrillator Implantation Trial)-I in 1996 5 and the MUSTT (Multicenter Unsustained Tachycardia Trial) in 1999. 6 After the publication of the first guidelines in 2001, investigators in Europe and the United States published the results of clinical studies of ICD therapy for primary prevention of SCD such as the MADIT-II in 2002 7 and the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) in 2005. 8 The indications of ICD therapy for primary prevention of SCD were expanded accordingly. In Japan, indications of ICD therapy for secondary prevention of SCD were clearly described, and that for primary prevention of SCD were expanded to patients who have symptomatic heart failure and ventricular dysfunction in the 2006 edition of the guidelines. With the technical advantages and miniaturization of the devices, more patients started to receive ICD therapy, and the guidelines were required to revise to reflect new evidence. In 2007, the Japanese Circulation Society (JCS) published the "Guidelines for Diagnosis and Management of Patients with Long QT Syndrome and Brugada Syndrome (JCS 2007) 9 ", which described the indications of ICD therapy for the prevention of fatal arrhythmias in these patient populations. The present guidelines had to be revised to reflect these indications.
In parallel with the advancement of ICD therapy, biventricular pacing, which is referred to as cardiac resynchronization therapy (CRT) was developed and advanced as a treatment for patients with chronic heart failure associated with intraventricular conduction disturbance. A lot of clinical studies have demonstrated that CRT is effective in alleviating symptoms and improving exercise capacity and life prognosis especially in patients who have wide QRS complexes of left bundle branch block pattern, chronic heart failure (New York Heart Association [NYHA] Class III or IV symptoms) and ventricular dysfunction. In the United States, the Food and Drug Administration (FDA) approved CRT in 2001, and CRT device that incorporates both pacing and defibrillation capabilities (CRT-D) in 2002 according to the results of the COMPANION (Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure) study in which CRT-D was demonstrated to improve life prognosis of patients with chronic severe heart failure by preventing death due to heart failure and sudden death. 10 In Japan, CRT and CRT-D were included in the National Health Insurance (NHI) price list in 2004 and 2006, respectively. Following the publication of the 2006 edition of the guidelines, investigators reported the benefits of CRT-D in patients with wide QRS complexes, ventricular dysfunction, and mild or moderate heart failure (NYHA Class II or III symptoms), and the investigators of the RAFT (ResynchronizationDefibrillation for Ambulatory Heart Failure Trial) in 2010 demonstrated that CRT-D was more effective than ICD in improving life prognosis in patients with NYHA Class II symptoms of heart failure. 11 The guidelines should be revised to provide up-to-date indications of CRT and CRT-D, and we also have to consider the criteria for the indication of CRT such as the width of QRS complex, level of cardiac function, severity of heart failure and complication of AF.
With the recent advancement of medical engineering, nonpharmacotherapy of cardiac arrhythmias have improved significantly, and evidence supporting widespread use of such procedures has been obtained in many large-scale clinical studies. We thus modified the 2006 edition of the guidelines to prepare the 2011 edition.
Current Status of Non-Pharmacotherapy of Cardiac Arrhythmias
In Japan, the use of implantable pacemakers for the treatment of bradyarrhythmia started to be covered with the NHI in 1974. Catheter ablation has been established as a minimally invasive, curative technique to target the sources of arrhythmia. In the United States, about 400,000 people die from SCD each year, and 80 to 90% of them are considered to have ventricular fibrillation/tachycardia, 13, 14 and ICD therapy is positioned as the most effective preventive measure against sudden death. The presence of intraventricular conduction disturbance of left bundle branch block pattern, a finding observed in 20 to 30% of patients with chronic heart failure, was found to be an independent prognostic factor, and CRT (i.e., biventricular pacing) was established and rapidly becoming common in Europe and the United States. CRT-D were also developed on the basis of the finding that sudden death accounted for 40 to 50% of the deaths in patients with chronic heart failure, and ventricular fibrillation was considered the most common cause of sudden death in this population. In Japan, catheter ablation, ICD therapy, CRT and CRT-D therapy were started to be covered with the NHI in 1994, 1996, 2004 and 2006, respectively (Figure 1) . These non-pharmacological procedures are rapidly improving, and the numbers of patients receiving ICD therapy and CRT/CRT-D therapy have been increasing every year (Figure 2) . Although much is still not known for SCD in Japan, 15 it is estimated that 60,000 to 80,000 people died from it each year. Although investigators believe that the most common direct cause of SCD is ventricular tachyarrhythmia, 16,17 but the distribution of underlying heart diseases in Japanese patients differ from that in Western patients. 18 Coronary artery disease is less common, and dilated cardiomyopathy, hypertrophic cardiomyopathy and idiopathic ventricular fibrillation are more common in Japanese patients (Figure 3) . Physicians should select the most appropriate option from drugs and various non-pharmacological procedures including catheter ablation, ICD therapy and surgery to treat patients with tachyarrhythmia. It is of great clinical significance to provide updated guidelines for non-pharmacotherapy of patients with tachyarrhythmia.
Contents of the Guidelines
The present revised guidelines propose indications for nonpharmacological procedures for the treatment of cardiac arrhythmias according to the latest findings. The present guidelines describe the significance and indications of clinical cardiac EPS, which is essential to determine whether non-pharmacological procedures are indicated and assess the efficacy of such procedures, and list indications of cardiac pacing, catheter ablation, ICD therapy, CRT-D therapy and surgery. The guidelines also describe cardiac pacing for patients with hypertrophic obstructive cardiomyopathy and biventricular pacing (i.e., CRT) for patients with heart failure.
It is difficult to provide evidence-based recommendations for non-pharmacotherapy of children with tachyarrhythmia because they are extremely small in number and few clinical studies have been conducted in this patient population. In the present guidelines, many recommendations on the indications Figure 1 . History of pharmacotherapy and non-pharmacotherapy of cardiac arrhythmias. 3D, three-dimensional; CAST, Cardiac Arrhythmia Suppression Trial; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy device that incorporates both pacing and defibrillation capabilities; ICD, implantable-cardioverter defibrillator; NHI, National Health Insurance; WPW, Wolff-Parkinson-White. JCS Joint Working Group of catheter ablation and ICD therapy in children are graded considering the particularity of these procedures according to the consensus of the members of Joint Working Groups.
Evidence and Class of Recommendations
In Japan, non-pharmacological procedures for the treatment of arrhythmias other than cardiac pacing have not been exten- Figure 2 . Changes over time of cases of ICD therapy and CRT in Japan: total cases of new implantation and replacement. CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy device that incorporates both pacing and defibrillation capabilities; CRT-P, cardiac resynchronization therapy device that provides pacing but not defibrillation capability; ICD, implantable-cardioverter defibrillator; NHI, National Health Insurance. Figure 3 . Distribution of underlying heart diseases among patients undergoing ICD therapy in Japan and the United States. ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; ICD, implantable-cardioverter defibrillator. Modified from Kasanuki H. Indications for ICD. In: Implantable Cardioverter Defibrillator Assessment Committee of the Japanese Society of Cardiac Pacing and Electrophysiology, editor. Clinical practice of implantable cardioverter defibrillators. p24. Igaku-Shoin Ltd., Tokyo, 1998. 18 JCS Guidelines for Non-Pharmacological Therapy of Arrhythmias sively developed and not commonly used. Evidence on the benefits of non-pharmacological procedures for the treatment of arrhythmias is thus limited. In the preparation of the present guidelines, we reviewed the literature providing evidence in Europe and the United States, critically examined the level of evidence, and collected data in Japan to discuss the relevant literature and data at the Joint Working Groups meetings and determine the level of evidence according to the experience and opinions of the members of Joint Working Groups and collaborators. Although the Joint Working Groups reviewed previous and latest American College of Cardiology/American Heart Association (ACC/AHA) guidelines 19-23 as well as guidelines by the Canadian Diabetes Association 24 as references, we did not provide level of evidence in the present guidelines as in the previous editions 25-27 since it is difficult to evaluate evidence available in Japan. The following Class of Recommendations are used in the present guidelines, according to the grading system used in ACC/AHA guidelines as well as the four-rank grading proposed by the Canadian Diabetes Association.
Class I:
There is evidence and/or general agreement that a given procedure or treatment is useful and indicated. 2. Class IIa: Weight of opinion is in favor of usefulness. 3. Class IIb: Usefulness is less well established by opinion. 4. Class III: General agreement that the procedure or treatment is not useful or may even be harmful and is not indicated.
Matters to Be Considered in Determining the Indications for Non-Pharmacotherapy
Non-pharmacotherapy of cardiac arrhythmia is performed to 1) prevent SCD and improve life prognosis (reduce mortality); 2) alleviate symptoms related to arrhythmias and improve wellbeing (reduce morbidity); and 3) improve satisfaction with social life of the patients. The items 2) and 3) are necessary to improve the quality of life (QOL) of the patients. In other words, non-pharmacological procedures should therefore be evaluated and selected from the medical (biological) and social aspects of each patient. The medical aspects include whether the patient has Adams-Strokes attack (symptoms of cerebral ischemia such as syncope and dizziness with black out), palpitations, chest distress, chest pain, symptoms of heart failure, and hemodynamic instability in association with arrhythmias and whether these symptoms may become fatal. Also, the patient should be evaluated for the presence and severity of underlying heart diseases, cardiac functions, type of arrhythmias (tachyarrhythmia or bradyarrhythmia), and effects of drugs and exercise, and should undergo clinical EPS, signal-averaged electrocardiography (ECG), and T wave alternans measurement and others. The social aspects should be evaluated to understand his or her personality and what makes him/her satisfied and what he/she wants in the workplace, community and home. Physicians should consider the patient's occupation (e.g., airline pilot, car/ train driver, or a worker engaged in potentially hazardous activities such as high place work); younger people; especially desire to continue sports, become pregnant, and/or drive; living place (whether living in a remote place where access to medical services is limited); frequency of recreational travel or business trip (especially overseas business trips facing time differences); and stress during work (whether having a physically and mentally demanding job).
Requirements for Physicians Providing Non-Pharmacological Procedures of Arrhythmias
Non-pharmacological procedures of arrhythmias are rapidly evolving field and require advanced medical techniques. Procedures listed in the present guidelines must be performed by experienced physicians in suitable medical institutions. Physicians must meet the following requirements:
1. Physicians must have sufficient knowledge and experience in clinical cardiac EPS. 2. Physicians must have sufficient knowledge and experience in treatment with anti-arrhythmic drugs. 3. Physicians must have sufficient knowledge and medical techniques in non-pharmacological procedures for the treatment of arrhythmias such as cardiac pacing, catheter ablation, ICD therapy, CRT/CRT-D therapy and surgeries, and must be able to conduct emergency surgery or other appropriate measures to cope with complications.
Implantable-Cardioverter Defibrillator
In the NHI Price List 2010, the following requirements for medical institutions are set for reimbursement of fee for ICD implantation. cases of open heart surgery, coronary bypass surgery or aortocoronary bypass surgery annually and a minimum of 10 cases of pacemaker implantation annually. 4. Medical institutions shall have a minimum of two full-time cardiologists and two full-time cardiovascular surgeons, and at least two of them must have completed required training.
Catheter Ablation
In 1990, the Japanese Society of Cardiac Pacing and Electrophysiology (currently named: the Japanese Heart Rhythm Society) proposed the following requirements for medical institutions performing catheter ablation, 28 many of which are still valid. Catheter ablation, which is referred to as percutaneous catheter-based ablation of the myocardium in the NHI Price List, is listed as a Category 1 procedure required to be performed in institutions that meet the following standards for those performing procedures listed in the items 5 and 6 of the General Rules of the Chapter 2, Section 10: Surgeries in of the NHI ing patients with severe heart failure using mechanical cardiac assist systems including external devices. 5. Medical institutions shall have a minimum of two full-time cardiologists and two full-time cardiovascular surgeons, and at least two of them must have completed required training.
In addition to the above requirements, it is necessary to ensure appropriate human resources, equipment, and operating systems with the aim of performing non-pharmacological procedures effectively and safely.
In Japan, the Japanese Heart Rhythm Society has hold education/training seminars on catheter ablation, ICD therapy, CRT/CRT-D therapy, and others to provide basic/standard knowledge and up-to-date information. The Japanese Heart Rhythm Society and the Japanese Society of Electrocardiology are cooperatively developing a system to certify specialists in cardiac arrhythmia who can provide appropriate and up-to-date treatment, and will implement the certification system in 2012. Also, the Japanese Heart Rhythm Society has provided "Cardiac Pacemaker Technician Training Seminars" to foster healthcare professionals specialized in cardiac arrhythmia, EPS, pacemaker therapy, ICD/CRT-D therapy, catheter ablation and other advanced techniques, and issued certificates of Cardiac Device Representatives (CDR) who are working in manufactures of cardiac devices such as pacemaker and ICD to provide device information.
Informed Consent
When a patient decides whether he/she will receive advanced medical technique treatment such as non-pharmacotherapy of cardiac arrhythmia, he/she must be fully explained the treatment in words which can be understood and express informed consent to treatment of his/her own will. Although information provided should be selected by individual physicians based on their knowledge and experience and may differ among physicians, the following information should be provided, basically: 1) Information about the disease (e.g., type and severity of arrhythmia, and underlying heart disease); 2) Information about the contents of treatment procedures and its effects (in addition to general information, the results in the medical institution should be provided) such as the purpose and contents of treatment procedures (including the model name and manufacturer of the pacemaker, ICD or CRT/CRT-D to be used), the clinical efficacy and success rate; the type, severity and incidence of acute phase complications; the type, severity and frequency of long-term complications, and reasons for selection of the treatment procedure; 3) Information about alternative treatment procedures (pharmacotherapy, other non-pharmacological procedures, and procedures also available in other institutions) and their expected effects (e.g., success rates and complications for the procedures mentioned); 4) Information about consequences when the disease is left untreated without undergoing the treatment procedure (e.g., expected outcomes and likelihood); and 5) Information about the position of the treatment procedure for different types of arrhythmias, the possibility of occurring unexpected short-and long-term complications), and expected advancement of antiarrhythmic treatment in the future. When the patient seeks second opinions by other physicians and medical institutions, the physician must cooperate with the patient.
However, it is not easy to provide the above information to patients undergoing non-pharmacotherapy of cardiac arrhythmia in the clinical setting due to some incompleteness of the current medicine, limited knowledge and experience of the attending physician, or the attending physician's concern that explanation may lead to confusion. Selection of appropriate and necessary contents to be communicated is an important issue. It is expected that medical institutions will be required to disclose whether the institution meets the relevant requirements and the physicians have been certified by the relevant academic societies as well as the number of cases and the results (success rates and incidence of complications) in the future.
Although the "will of the patient" is the most important factor in determining whether non-pharmacotherapy of cardiac arrhythmia should be performed, physicians should not overestimate the "strong desire" and "unwillingness" of the patient since he/she may have made his/her decision based on biased medical information. Physicians should be committed to be able to clearly explain accurate and up-to-date information to the patients and their family members based on the level of their understanding, and should be aware that informed consent is an only opportunity for the patient to weigh the merits and demerits of the treatment procedure and select a way to experience the "true benefits". 
Cardiac Electrophysiological Study to Evaluate the Efficacy of Pharmacotherapy for Tachyarrhythmia
Class I None. The efficacy of drugs is evaluated by their ability in preventing the inducibility of tachycardia during EPS. This style of treatment is referred to as EPS-guided antiarrhythmic therapy. Although it has been reported that EPS-guided or Holter ECGguided therapy is useful to ensure the efficacy of amiodarone, 35 empiric therapy is still prevalent. In the AVID (Antiarrhythmics Versus Implantable Defibrillators) study, 36 ICD therapy was superior in improving the prognosis as compared to pharmacotherapy for secondary prevention of ventricular tachycardia/ fibrillation. Since ICD therapy is now quite common, EPSguided therapy only plays a supplemental role such as reducing the incidence of recurrence. The risk of sudden death is assessed by examining whether fatal arrhythmia may be induced or not, but it is not easy to specify high-risk patients. It should be evaluated comprehensively using Holter ECG, exercise stress tests, signal-averaged ECG, and T wave alternans measurement. Risk assessment using EPS should be actively conducted in patients with nonsustained ventricular tachycardia who have structural heart disease and left ventricular dysfunction. 37-40 EPS are less useful in risk assessment in patients with LQTS. There is controversy regarding whether electrical induction of ventricular fibrillation should be used or not to assess the risk in patients showing Brugada type ECG. It is believed that EPS are less useful in patients with frequent episodes of premature ventricular contractions without structural heart disease.
Class IIa

II Clinical Cardiac Electrophysiological Study JCS Joint Working Group
Since the launch of commercially available implantable pacemakers in the 1960 s, the devices have been improved year by year, and smaller sophisticated devices have been launched. With the rapid downsizing, pacemakers have significantly advanced in terms of function. Currently-available devices can mimic physiological heart rates almost completely using AV sequential pacing and rate responsive pacing. Although permanent cardiac pacing has been established as the leading treatment method for bradyarrhythmia that is far more beneficial than other procedures including pharmacotherapy and is being used to improve the life prognosis and QOL, investigators have pointed out ethical and economic problems caused by overuse. In the light of these problems, physicians have called for more strict guidelines for the use of implantable pacemakers. In the United States, the ACC/AHA Task Force published the first guidelines for implantation of cardiac pacemakers and antiarrhythmia devices in 1984 which were substantially revised in 1991 and 1998 19,20 before publishing the latest revision. In Japan, physicians have considered the use of implantable devices according to the AHA/ACC guidelines, but the Japanese Society of Cardiac Pacing and Electrophysiology (currently named: the Japanese Heart Rhythm Society) published its guidelines for implantation of cardiac pacemakers in 1995. 41 When cardiac pacing is considered, it is most important to understand the nature and severity of symptoms and a causal relationship between symptoms and bradyarrhythmia. Symptoms of bradyarrhythmia include syncope, black out, severe dizziness, and lightheadedness caused by transient cerebral ischemia, and decreased exercise capacity and symptoms of heart failure caused by long-lasting bradycardia. Physicians should also assess their patients for underlying cardiac diseases that may be exacerbated by bradycardia, and cerebrovascular lesions that may lead to cerebral infarction when bradycardia occurs, especially when they need treatment with drugs that may exacerbate bradycardia. Abnormal findings of Holter ECG and cardiac EPS are important as well.
Physicians should also consider the age, occupation (e.g., working in places easily exposed to electromagnetic interference and high places, car drivers), physical activity, family environment, living environment, personality, and patient's and his/her family members' desire. 
Atrioventricular Block
III Cardiac Pacing JCS Guidelines for Non-Pharmacological Therapy of Arrhythmias
Class IIb 1. Patients with first degree AV block associated with heart failure in whom pacing at an optimal AV interval is expected to improve hemodynamics. 
Bifascicular or Trifascicular Block
Sick Sinus Syndrome
Class I 1. Patients with symptoms such as syncope, convulsion, black out, dizziness, shortness of breath and easy fatigability, or heart failure that have been confirmed due to bradycardia, sinoatrial block, or sinus arrest associated with sinus node dysfunction or blunted heart rate response during exercise, including patients whose symptoms are caused by long-term treatment with drug(s) which cannot be discontinued.
Class IIa 1. Patients with the above-mentioned symptoms as well as bradycardia and/or ventricular arrest, but the relationships between these are unclear. 2. Patients with bradycardia-tachycardia syndrome in whom drugs to control tachycardia exacerbate bradycardia.
Class IIb
1. Asymptomatic patients with sinoatrial block or sinus arrest.
Bradycardic Atrial Fibrillation
Class I 1. Patients with symptoms such as syncope, convulsion, black out, dizziness, shortness of breath and easy fatigability, or heart failure that have been confirmed due to bradycardia or ventricular arrest, including patients whose symptoms are caused by long-term treatment with drug(s) which cannot be discontinued.
Class IIa 1. Patients with the above-mentioned symptoms as well as bradycardia and/or ventricular arrest, but the relationships between these are unclear. 
Hypersensitive Carotid Sinus Syndrome and Reflex Syncope
Pacing in Children
The most common indications for permanent pacemaker implantation in children are 1) symptomatic sinus bradycardia, 2) bradycardia-tachycardia syndrome, and 3) high-grade or complete AV block. Although the general indications for pacemaker implantation in children are similar to those in adults, there are several important considerations in young patients: 1) Patients with prior congenital heart surgery may have symptoms due to sinus bradycardia or loss of AV synchrony at heart rates, 55,56 and appropriate heart rates, which differ from those for children with normal cardiovascular physiology, should be set; 2) the clinical significance of bradycardia is age dependent; 3) transvenous lead implantation may be extremely difficult among infants and young children or children with venous anomaly or congenital heart disease, and epicardial pacing lead implantation should be considered; and 4) because there are no randomized clinical studies of cardiac pacing in children or patients with congenital heart disease, the Level of Evidence for most recommendations is C. Additional details that need to be considered in pacemaker implantation in children include risk of paradoxical embolism due to thrombus formation on an endocardial lead system. 57 Physicians should also select an appropriate lead implantation technique to reserve the transvenous routes for future use.
Indications for Permanent Pacing in Children and Patients
With Congenital Heart Disease Class I 1. High-grade or complete AV block associated with symptomatic bradycardia, ventricular dysfunction, or low cardiac output. 2. Sinus node dysfunction with correlation of symptoms during age-inappropriate bradycardia (the definition of bradycardia varies with the patient's age and target heart rate). 3. High-grade or complete AV block that persists at least 7 days after cardiac surgery. 4. Congenital complete AV block with a wide QRS escape rhythm, premature ventricular contractions, or ventricular dysfunction. 5. Congenital complete AV block in the infant with a ventricular rate less than 55 bpm or with congenital heart disease and a ventricular rate less than 70 bpm.
Class IIa 1. Patients with congenital heart disease and sinus node dysfunction who have recurrent episodes of intra-atrial reentrant tachycardia (sinus node dysfunction may be intrinsic or secondary to antiarrhythmic treatment). 2. Congenital complete AV block beyond the first year of life with an average heart rate of 50 bpm or less, abrupt pauses in ventricular rate that are 2 or 3 times the basic cycle length, or associated with symptomatic bradycardia. 3. Sinus bradycardia with complex congenital heart disease with a resting heart rate of 40 bpm or less, or abrupt pauses in ventricular rate longer than 3 seconds. 4. Patients with congenital heart disease and impaired hemodynamics due to sinus bradycardia or loss of AV synchrony. 5. Syncope of unknown etiology in the patients with prior congenital heart surgery complicated by transient AV block and residual bundle branch block. 59 and STAF (Strategies of Treatment of Atrial Fibrillation) studies 60 mainly in patients with persistent AF, no differences were found between the two approaches in terms of life prognosis. In the J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) study, 61 a clinical study conducted in Japan mainly in patients with paroxysmal AF, there were no significant differences between the two approaches in terms of mortality, incidence of cerebral infarction, and hospitalization rate. However, the prognosis was better in patients maintaining sinus rhythm in a subanalysis of the AFFIRM study, and the results suggest that any beneficial antiarrhythmic effects of antiarrhythmic drugs are offset by their adverse effects. 62 On the other hand, many studies have reported that pulmonary vein isolation ablation is better than pharmacotherapy of arrhythmia in terms of maintaining sinus rhythm. 90 In the present guidelines, catheter ablation for patients symptomatic drugresistant paroxysmal AF is listed as a Class I indication provided that "this procedure is performed in medical institutions performing a minimum of 50 catheter ablation procedures annually", since advanced technique, experience and equipment are necessary to ensure the safe and consistent implementation of this procedure. Evidence regarding the usefulness of catheter ablation has been obtained in medical institutions with a large number of procedures, and constant implementation is believed to be related to the efficacy and safety of catheter ablation for AF. Catheter ablation of persistent AF is effective in 20 to 61% of patients undergoing pulmonary vein ablation only, and 9 to 85% of patients receiving complex fractionated atrial electrogram (CFAE) ablation. 66,79,91-93 Pulmonary vein ablation alone is not sufficiently effective, and pulmonary vein ablation in combination with CFAE ablation or linear ablation is expected to be effective and require no pharmacotherapy in 47 to 95%, and to achieve maintaining sinus rhythm in about more than 70% of patients. 81,85,94-99
Class IIb
A long-term study has reported that 79.5% of patients with paroxysmal AF and normal left ventricular function maintained sinus rhythm about 5 years after extensive pulmonary vein isolation (some patients underwent repeated procedures), and clinical improvement was observed in 92.5%. 100 In another study in patients with paroxysmal (51%) and nonparoxysmal (49%) AF undergoing extensive pulmonary vein isolation (some JCS Joint Working Group underwent additional linear ablation), 87% of patients maintained sinus rhythm 2 years after ablation (72% achieved AF elimination without antiarrhythmic drugs, and 15% needed antiarrhythmic drugs), and 13% had recurrent AF. QOL scores started to improve significantly at month 3, and continued for 2 years. 101 In a retrospective analysis in patients after successful catheter ablation of AF, the incidences of cerebral embolism and massive bleeding during the follow-up period of about 2 years were significantly lower in patients who discontinued anticoagulation therapy 3 to 6 months after ablation than patients who continued anticoagulation therapy. 102 Patients with a high risk of thromboembolism should continue anticoagulation therapy after catheter ablation. 103 Atrial flutter is a type of supraventricular tachycardia characterized by a regular flutter wave morphology with an atrial rate of about 300 bpm (240 to 440 bpm). Atrial flutter is classified into type I and type II: the atrial rate is relatively slow (240 to 340 bpm) in type I and faster (350 to 450 bpm) in type II. Many cases of type I atrial flutter, referred to as "typical atrial flutter", are macro-reentrant right atrial tachycardia that involves circulation of the reentrant impulse around the tricuspid annulus, and the ECG displays a sawtooth waveform in the inferior leads. Typical atrial flutter is further divided into two subtypes, known as counterclockwise atrial flutter and clockwise atrial flutter based on the flutter wave polarity in the inferior leads (negative and positive, respectively). Atypical atrial flutter (i.e., type II atrial flutter) is caused by a macro-reentrant circuit rotating around an area other than the tricuspid annulus. Its clinical aspects are similar to AF but the mechanisms differ among subtypes. The severity of symptoms caused by atrial flutter depends on the rate of AV conduction. Although some patients remain asymptomatic, others may develop 1:1 AV conduction and syncope. Typical atrial flutter can be successfully treated with catheter ablation by creating a line of conduction block at the isthmus between the tricuspid annulus and the inferior vena cava. 104, 105 Since atypical atrial flutter other than right atrial flutter due to lower loop reentry 106 is right atrial isthmus-independent, targets of catheter ablation differ among patients. Atypical atrial flutter may be caused by intra-atrial reentry in some cases and abnormal automaticity in others. 3D mapping systems are useful to localize the reentry circuit and the origin of tachycardia, so as to examine thoroughly the pattern of conduction in the fluttering right or left atrium. Atrial tachycardia may arise from a focal origin, as in cases of abnormal automaticity (i.e., ectopic automaticity, and triggered activity) and micro-reentry, and from macro-reentry circuits in others. It is difficult to clearly differentiate the latter cases from isthmus-independent atrial flutter. 107-110 Atrial tachycardia arising from a focal origin includes sinus node reentry tachycardia, AV nodal reentrant tachycardia, and other types of reentry tachycardia. Abnormal automaticity is commonly observed in the pulmonary vein, superior vena cava, coronary veins, atrial appendage, crista terminalis, and others. 111 Catheter ablation is recommended even for asymptomatic patients since longlasting atrial tachycardia may induce left ventricular dysfunction by causing tachycardia-induced cardiomyopathy.
Atrial Flutter and Atrial Tachycardia
Atrial Tachycardia
Atrioventricular Junction Ablation for Supraventricular Tachyarrhythmia
Class I 1. Patients with supraventricular tachyarrhythmia who have serious symptoms or severe ventricular dysfunction due to tachycardia, in whom pharmacotherapy is ineffective or cannot be continued due to adverse drug reactions and for whom conventional catheter ablation for supraventricular arrhythmia was not successful or cannot be performed.
Class IIa
1. Patients with supraventricular tachyarrhythmia and substantial deterioration of QOL in whom pharmacotherapy is ineffective or difficult to perform and for whom conventional catheter ablation for supraventricular arrhythmia was not successful or cannot be performed.
Class III
1. Patients in whom AV conduction should be maintained considering the risk and benefit of the procedure.
Premature Ventricular Contraction
Class I 1. Patients in whom premature ventricular contraction trigger polymorphic ventricular tachycardia or ventricular fibrillation and in whom pharmacotherapy is ineffective or cannot be continued due to adverse drug reactions. JCS Guidelines for Non-Pharmacological Therapy of Arrhythmias Frequent premature ventricular contractions may cause ineffective biventricular pacing in patients receiving CRT. Treatment of premature ventricular contraction may improve ventricular dysfunction by improving the efficacy of biventricular pacing. 118 Catheter ablation may be considered for patients with frequent premature ventricular contractions originating from the ventricular outflow tract and patients with ventricular dysfunction. 119 
Ventricular Tachycardia
Class I 1. Patients with monomorphic ventricular tachycardia associated with ventricular dysfunction or heart failure in whom pharmacotherapy is ineffective or cannot be continued due to adverse drug reactions. 2. Patients with frequent ICD discharges and in whom pharmacotherapy is ineffective or cannot be continued due to adverse drug reactions. 3. Patients in whom CRT is not effective due to ineffective biventricular pacing caused by monomorphic ventricular tachycardia and pharmacotherapy is ineffective or cannot be continued due to adverse drug reactions. 4. Patients with symptomatic idiopathic ventricular tachycardia and deterioration of QOL who desire to undergo catheter ablation even though pharmacotherapy is effective or has not been initiated.
Class IIa
1. Patients with asymptomatic idiopathic ventricular tachycardia originating from the ventricular outflow tract and an extremely rapid heart rate.
Patients with idiopathic ventricular tachycardia originating
from the ventricular outflow tract who desire to undergo catheter ablation even though pharmacotherapy is effective or has not been initiated. 
Special Considerations for Children
The use of catheter ablation for children should be carefully considered on the basis of the indications for adult patients with arrhythmias as well as specific features in children. 25, 137 In children, catheter ablation is conducted for the treatment of severe conditions such as arrhythmias associated with congenital heart diseases 138, 139 and incessant tachycardia complicated by tachycardia-induced ventricular dysfunction. 140 It is desirable that these patients be treated with physicians who have experience and knowledge in the treatment of congenital heart disease and catheter ablation for children.
Class I
1. Children with WPW syndrome or ventricular tachycardia who have a history of near-miss sudden death or syncope. 2. Children with supraventricular tachycardia or ventricular tachycardia who have ventricular dysfunction due to sustained tachycardia. 3. Children with hemodynamically significant drug-resistant ventricular tachycardia.
Class IIa
1. Children with drug-resistant recurrent or symptomatic supraventricular tachycardia. 2. Children with tachycardia associated with congenital heart diseases (especially in children in whom catheterization would be difficult after surgery). 3. Children with incessant supraventricular tachycardia. 4. Children with intra-atrial reentrant tachycardia. 5. Children with palpitation in whom supraventricular tachycardia is induced during cardiac EPS. 6. Children with WPW syndrome who or whose family member desire to undergo catheter ablation after careful consideration of the natural history and complications of the disease.
Class IIb 1. Children with supraventricular tachycardia responding to pharmacotherapy. 2. Catheter ablation of AV junction and pacemaker implantation in children with recurrent or drug-resistant intra-atrial reentrant tachycardia in whom prior catheter ablation was failed (consider referral to a medical institution with a large number of cases). 3. Children with ventricular tachycardia for which pharmacotherapy is effective but abnormal hemodynamics remain. 4. Children with nonsustained ventricular tachycardia or nonsustained supraventricular tachycardia. 142 The mean left ventricular ejection fraction (LVEF) among patients enrolled in these studies ranged 32 to 45%. It is expected that ICD therapy are especially effective among patients with a LVEF of 35% or less.
ICD therapy may not always be indicated for patients with acute coronary syndrome (ACS), 143 since sustained ventricular tachycardia and ventricular fibrillation developing in the acute phase of ACS (the first 48 hours after onset) often do not recur after ischemia is treated and the arrhythmic substrate is stabilized.
Sustained Ventricular Tachycardia and Ventricular
Fibrillation Associated With Nonischemic Dilated Cardiomyopathy Prospective clinical studies conducted until now have demonstrated that ICD therapy is superior to antiarrhythmic drugs in improving the life prognosis in patients with sustained ventricular tachycardia and ventricular fibrillation associated with nonischemic dilated cardiomyopathy as in in the case of patients with coronary artery diseases. 36,141,142
Primary Prevention in Patients With
Structural Heart Disease Class I 1. Patients with chronic heart failure due to coronary artery disease or dilated cardiomyopathy who have NYHA Class II or III symptoms of heart failure, a LVEF of 35% or less and nonsustained ventricular tachycardia. 2. Patients with NYHA Class I symptoms of heart failure who have left ventricular dysfunction (LVEF of 35% or less) associated with coronary artery disease or dilated cardiomyopathy and nonsustained ventricular tachycardia in whom sustained ventricular tachycardia or ventricular fibrillation induced during EPS.
Class IIa
1. Patients with chronic heart failure associated with coronary artery disease or dilated cardiomyopathy who have NYHA
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Class II or III symptoms of heart failure despite appropriate pharmacotherapy and a LVEF of 35% or less.
Class III 1. Patients with idiopathic nonsustained ventricular tachycardia not associated with structural heart diseases.
Large-scale prospective clinical studies have been conducted mainly in Europe and the United States, 5-8,144,145 to assess the effects of ICD therapy for primary prevention of SCD in patients at a high risk of sudden death (i.e., patients with low LVEF or NYHA Class II or III symptoms of heart failure).
Primary Prevention of SCD in Patients With Coronary Artery Disease
The results of clinical studies conducted mainly in Europe and the United States support widespread use of ICD therapy for patients with coronary artery disease and low LVEF. On the other hand, cohort studies to evaluate the prognosis of patients with coronary artery disease in Japan have reported that patients have relatively favorable life prognosis and the incidence of sudden death is low. 146,147 Accordingly, extended ICD indications supported in Europe and the United States may not be so cost-effective in Japan.
Also, it has been demonstrated that the efficacy of ICD therapy is higher in patients with a longer period from the onset of myocardial infarction. ICD implantation as a primary prevention method should be performed in patients who survived their first myocardial infarction for at least one month.
Primary Prevention of Sudden Cardiac Death in Patients
With Nonischemic Dilated Cardiomyopathy The results of clinical studies conducted in Europe and the United States indicated that although ICD therapy was effective in terms of the decrease in mortality in patients with nonischemic dilated cardiomyopathy associated with heart failure, the decrease was not statistically significant 8 . A meta-analysis of 5 studies on the effects of ICD therapy in this patient population indicated that relative mortality decreased by 31% with ICD therapy. 148 In a cohort study of the prognosis of patients with chronic heart failure in Japan, SCD occurred in 15% of patients with heart failure (LVEF less than 30%). 149 It is thus considered that the prognosis and incidence of SCD in patients with nonischemic dilated cardiomyopathy in Japan are similar to those in Europe and the United States.
Syncope of Unknown Etiology
Class I 1. Patients with chronic heart failure associated with coronary artery disease or dilated cardiomyopathy who have NYHA Class II or III symptoms of heart failure and an LVEF of 35% or less despite appropriate pharmacotherapy.
Class IIa 1. Patients with moderate ventricular dysfunction (LVEF 36
to 50% and NYHA Class I symptoms) associated with coronary artery disease or dilated cardiomyopathy in whom ventricular tachycardia/fibrillation is induced during EPS.
Class III
1. Patients without ventricular dysfunction in whom the presence of causes of fatal arrhythmias such as hypertrophic cardiomyopathy, Brugada syndrome (including drug-induced Brugada syndrome), preexcitation syndrome and short QT syndrome is excluded, and ventricular tachycardia/fibrillation is not induced during EPS.
Since ventricular tachycardia/fibrillation are major and significant causes of syncope, ICD therapy is indicated for patients with syncope suspected to be due to ventricular tachycardia/ fibrillation. Even patients with mild or moderate ventricular dysfunction (LVEF 36 to 50%) due to coronary artery disease or nonischemic dilated cardiomyopathy and NYHA Class I symptoms should be considered at a high risk of sudden death when ventricular tachycardia/fibrillation is induced during EPS, and may be indicated for ICD therapy. Hypertrophic cardiomyopathy is an important myocardial disease that causes sudden death especially in young patients under 40 years of age, and is often inheritable. 154, 155 Since patients with a history of sustained ventricular tachycardia or ventricular fibrillation have a recurrence rate of about 10% per year, widespread use of ICD therapy is recommended. 156 It has been reported that major risk factors for consideration of primary prevention with ICD therapy include nonsustained ventricular tachycardia; a family history of sudden death; syncope; a left ventricular wall thickness of 30 mm or more; and abnormal blood pressure response during exercise. Arrhythmogenic right ventricular cardiomyopathy/dysplasia is a major underlying heart disease that may cause SCD in young patients. 157-161 Factors predicting appropriate ICD discharge include a history of cardiac arrest and hemodynamically unstable sustained ventricular tachycardia. 162 Regarding the use of the ICD for primary prevention of SCD, a history of syncope is believed to predict appropriate ICD discharge. It has been reported that the 3-year incidence of arrhythmic events in patients with symptomatic Brugada syndrome is about 30%, 164 while the incidence of sudden death is low in asymptomatic patients. 165-168 However, ICD therapy is considered even for patients in whom ventricular fibrillation has not been documented, when they have typical ECG findings of Brugada syndrome; a history of syncopal attacks; polymorphic ventricular tachycardia induced during programmed stimulation; or a family history of sudden death. Note: The efficacy of β-blockers should be evaluated according to symptoms and severity of QT prolongation during stress testing. β-blockers are considered ineffective in patients diagnosed with LQTS type 3 (LQT3).
Arrhythmogenic Right
ICD therapy for the treatment of LQTS should be considered in 1) patients with recurrent syncope not responding to β-blockers or other drugs, or patients resuscitated from sudden death; 2) patients whose first manifestation was resuscitated from cardiac arrest; 3) patients with a family history of SCD; and 4) patients with none-adherence to pharmacotherapy or patients meet the criteria for intolerance. 171 However, the ICD is not a curative therapy, and may cause mental disorder due to frequent ICD discharges after implantation. The indication for ICD implantation in children especially should be evaluated carefully. 172
Left Cervicothoracic Sympathetic Ganglionectomy for Congenital Long QT Syndrome Class I None. Although few patients have undergone left cervicothoracic sympathetic ganglionectomy in Japan, this procedure has been used to treat drug-resistant patients in Europe and the United States, and favorable results have been reported in the treatment of drug-resistant congenital LQTS. 173-175
Class IIb
Implantable Cardioverter-Defibrillators in Children
Few children have undergone ICD implantation 176 since the prevalence of fatal arrhythmia associated with structural heart disease such as ischemic heart disease is low among children, and the rate of resuscitation is lower in children than adults, 177 among other reasons. Since the most common causes of SCD in children include cardiomyopathy, congenital heart diseases and arrhythmias, 178 and SCD due to arrhythmia is especially common, 159,179 children receiving ICD implantation after resuscitation is expected to increase in the future. In fact, successful resuscitation of children has increased in Japan, since automated external defibrillator (AED) become widely available in Japan; public education was provided to emphasize the importance of basic life support (BLS); and the use of AED by emergency medical technicians and bystanders was allowed in 2003 and July 2007, respectively. In the schools, it is highly likely that children can survive without sequelae when teachers and nursing teachers try to resuscitate them using BLS and AED. The results of multicenter clinical studies of ICD therapy in children and patients with congenital heart disease have been published. 180 The following recommendations were prepared according to the guidelines for the diagnosis and treatment of arrhythmia in children proposed by the Japanese Society of Pediatric Cardiology and Cardiac Surgery 181 and the ACC/AHA/Heart Rhythm Society (HRS) 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. 54
Indications for ICD Implantation in Children and
Patients With Congenital Heart Diseases ICD implantation in children is quite rare in Japan, and in most cases ICD implantation is conducted for secondary prevention.
Class I
1. Patients resuscitated from cardiac arrest after evaluation to define the cause of the event and to exclude any reversible causes. 2. Patients with symptomatic sustained ventricular tachycardia associated with congenital heart disease (catheter ablation or surgical repair may offer possible alternatives in carefully selected patients). Patients with heart failure may often develop intraventricular conduction disturbance, AV dyssynchrony, intraventricular dyssynchrony, and interventricular dyssynchrony. CRT with biventricular pacing can reduce these dyssynchrony conditions. CRT may prevent the progression of heart failure and improve the prognosis in patients with moderate or severe chronic heart failure who have cardiac contractile dysfunction and cardiac dyssynchrony. 219 However, CRT may not be effective in all patients with heart failure. Important factors predicting the efficacy of CRT include low LVEF and wide QRS complex on the ECG. Many clinical studies have been conducted in patients with a QRS interval of 120 to 150 msec. In the present guidelines, a wide QRS complex is defined as a QRS interval of 120 msec or more. CRT is highly effective in patients with a wide QRS complex of 150 msec or more (see below). Further studies are required to consider the indications of CRT in patients with mild heart failure. Although diagnostic imaging techniques such as echocardiography are expected to detect left ventricular contraction dyssynchrony, no standard criteria have been developed to detect the presence of dyssynchrony and evaluate responses to and effectiveness of CRT.
Class IIa
On the other hand, it is believed that CRT may decrease the total mortality of patients with heart failure but does not affect the incidence of SCD. 220 It has been reported that CRT with ICD backup may further decrease total mortality by preventing SCD. 221 CRT-D is recommended for patients who are indicated for both CRT and ICD (Class I or IIb).
Cardiac Resynchronization Therapy (CRT-P [CRT Device That Provides Pacing But Not Defibrillation Capability])
Class I 1. Patients with NYHA Class III or ambulatory Class IV symptoms of chronic heart failure despite optimal pharmacotherapy, a LVEF of 35% or less, a QRS interval of 120 msec or more, and sinus rhythm.
Class IIa 1. Patients with NYHA Class III or ambulatory Class IV symptoms of chronic heart failure despite optimal pharmacotherapy, a LVEF of 35% or less, a QRS interval of 120 msec or more, and AF. 2. Patients with NYHA Class III or ambulatory Class IV symptoms of chronic heart failure despite optimal pharmacotherapy, a LVEF of 35% or less, and who have received or are planned to receive permanent pacemaker implantation, and have depended on or are expected to require frequent ventricular pacing. The Maze procedure was developed as a curative treatment, and has improved to simplify the techniques, to ensure less invasive procedures and physiological recovery of atrial excitation such as by changing atrial incision lines, using cryoablation and radiofrequency energy alternative to surgical incisions, and simplifying the incision lines.
Class IIb
227-232
In patients with AF associated with mitral valve diseases, the incidence of postoperative cerebral infarction decreases when they receive the Maze procedure concomitant to mitral valve surgery. 233 The Maze procedure terminates AF by electrical isolation of the pulmonary veins in which rapid repetitive excitation is occurring, and by preventing reentry by atrial incision lines. Basically, AF may be terminated after pulmonary vein isolation only in some patients, 228 while sinus rhythm may not be restored after the Maze procedure in other patients. Further studies such as electrophysiological evaluation through intraoperative mapping should be conducted in the future. 234 Although surgical treatment of AF has become straightforward and less invasive using current ablation devices, 231 further advancement of the devices and development of reliable methods to verify successful conduction block are necessary. 235 
Other Supraventricular Tachycardia
